MannKind Corp (MNKD): Total Assets
$792.18M
As of 2025-12-31
$732.30M
As of 2026-06-30
+39.0%
3-year compound annual growth
+48.8%
5-year compound annual growth
+20.1%
10-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $792.18M | +101.1% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $393.84M | -17.1% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $475.20M | +60.9% | 2025-02-26, Balance as of period end |
| 2022-12-31 | $295.28M | -8.1% | 2024-02-27, Balance as of period end |
| 2021-12-31 | $321.16M | +195.7% | 2023-02-23, Balance as of period end |
| 2020-12-31 | $108.61M | +15.9% | 2022-02-24, Balance as of period end |
| 2019-12-31 | $93.72M | -13.0% | 2021-02-25, Balance as of period end |
| 2018-12-31 | $107.70M | +27.3% | 2020-02-25, Balance as of period end |
| 2017-12-31 | $84.58M | -21.0% | 2019-02-26, Balance as of period end |
| 2016-12-31 | $107.06M | -15.3% | 2018-02-27, Balance as of period end |
| 2015-12-31 | $126.41M | -68.0% | 2017-03-16, Balance as of period end |
| 2014-12-31 | $394.44M | +52.5% | 2016-03-15, Balance as of period end |
| 2013-12-31 | $258.65M | +2.9% | 2015-03-02, Balance as of period end |
| 2012-12-31 | $251.31M | +25.9% | 2014-03-03, Balance as of period end |
| 2011-12-31 | $199.55M | -28.0% | 2013-03-18, Balance as of period end |
| 2010-12-31 | $277.26M | n/a | 2012-03-15, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| MannKind Corp (MNKD) | 2025-12-31 | $792.18M | +101.1% |
| Arcutis Biotherapeutics, Inc. (ARQT) | 2025-12-31 | $432.97M | +24.1% |
| Sinovac Biotech Ltd (SVA) | 2025-12-31 | $8.54B | -30.8% |
| CorMedix Inc. (CRMD) | 2025-12-31 | $826.14M | +595.1% |
| Ardelyx, Inc. (ARDX) | 2025-12-31 | $501.60M | +15.1% |
| Evolus, Inc. (EOLS) | 2025-12-31 | $225.87M | -2.9% |
| Ironwood Pharmaceuticals Inc (IRWD) | 2025-12-31 | $396.90M | +13.1% |
| Innoviva, Inc. (INVA) | 2025-12-31 | $1.64B | +25.7% |
| Xeris Biopharma Holdings, Inc. (XERS) | 2025-12-31 | $383.53M | +18.7% |
Compare MNKD, ARQT, SVA, CRMD side by side · Screen every company in Pharmaceutical Preparations ↗